[Final confirmation of inefficiency of antibiotics in secondary prevention of coronary heart disease. Results of PROVE IT (gatifloxacin trial) and ACES].
E V
EV
Pokrovskaia
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017963:Azithromycin / Q000008:administration & dosage / Q000627:therapeutic use*; D002097:C-Reactive Protein / Q000032:analysis; D023521:Chlamydophila Infections / Q000150:complications / Q000188:drug therapy; D016993:Chlamydophila pneumoniae; D003327:Coronary Disease / Q000097:blood / Q000209:etiology / Q000401:mortality / Q000517:prevention & control*; D004311:Double-Blind Method; D024841:Fluoroquinolones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000077734:Gatifloxacin; D006801:Humans; D010919:Placebos; D016032:Randomized Controlled Trials as Topic; D013997:Time Factors
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D010919:Placebos; D017963:Azithromycin; D002097:C-Reactive Protein; D000077734:Gatifloxacin